VNDA Vanda Pharmaceuticals Inc.
13.53
+0.59 (+5%)
Previous Close
12.94
Open
12.94
Price To Book
2.43
Market Cap
720,795,705
Shares
53,273,888
Volume
650,596
Short Ratio
Av. Daily Volume
633,713
NewsSee all news
-
Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration to End Unnecessary and Scientifically Flawed Animal Toxicity Studies
WASHINGTON, Sept. 11, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
Phase 3 trial initiated 2Q 2019.
Tradipitant
Gastroparesis
PK trial initiated with full enrollment completed 4Q 2017.
HETLIOZ (tasimelteon) - pediatric formulation
Insomnia
Approved May 26, 2016.
Fanapt
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
Insomnia
CRL issued August 19, 2019.
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 1 initiated October 2018.
VTR-297
Hematologic malignancies
Phase 3 trial to be initiated 3Q 2019.
Tradipitant
Motion sickness
Randomized trial to commence in 2019.
Fanapt
Bipolar Disorder
Phase 2 trial to be initiated 3Q 2019.
HETLIOZ (tasimelteon)
Delayed sleep phase disorder (DSPD)
Latest News
-
Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration to End Unnecessary and Scientifically Flawed Animal Toxicity Studies
WASHINGTON, Sept. 11, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high